Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vivos Therapeutics, Inc. - Common Stock (NQ: VVOS )

3.290 -0.250 (-7.06%)
Streaming Delayed Price Updated: 3:13 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vivos Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., “New Strategic Model &amp; Key Regulatory Milestones Provide Revenue Tailwind”
December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New... 
Via TheNewswire.com
Exposures Product Safety
Why Vision Marine Technologies Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical Devices
Via Investor Brand Network
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
Via Benzinga
Exposures Fossil Fuels
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering. 
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Via Investor Brand Network
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000
Via Benzinga
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today
NVDA, TMUS, VVOS, SOFI, TSLA are the top trending stocks on Wednesday. 
Via Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17. 
Via Benzinga
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update
Via Investor Brand Network
VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024
VVOS stock results show that Vivos Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Alliance, Private Equity Investment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2024 Financial Report, Operational Update
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning! 
Via InvestorPlace
VVOS Stock Earnings: Vivos Therapeutics Reported Results for Q1 2024
Vivos Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2024 Results, Conference Call
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview
Via Investor Brand Network
Topics Product Recall
Exposures Legal Product Safety
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement
Via Investor Brand Network
What's Going On With Vivos Therapeutics Stock?
Vivos Therapeutics shares are trading lower Tuesday. The company filed a prospectus related to the resale of up to 1.73 million shares of common stock by selling shareholders. Vivos said that if the... 
Via Benzinga
Why Is Laser Photonics (LASE) Stock Up 130% Today?
Laser Photonics stock is rising higher on Tuesday as LASE investors celebrate a new unit order from L3Harris Technologies. 
Via InvestorPlace
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
Vivos Therapeutics stock is up on Tuesday as VVOS investors react to the company securing full Medicare reimbursement for its OSA device. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning! 
Via InvestorPlace
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.